Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data
Not entirely
Research focus How Reconstitution BAC is studied Summary of contexts in which this compound appears in the preclinical literature
Understanding how the AOD-9604 peptide works reveals a distinct metabolic approach that targets fat tissue directly without modifying hunger signals, cortisol levels, or appetite hormones
I have tried the semaglutide, tirzepatide, and the B12
